心衰规范化治疗_培训课件.pptVIP

Jessup, M. et?al. Calcium upregulation by percutaneous administration of gene therapy in?cardiac disease (CUPID): a phase?2 trial of?intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation 124, 304–313 (2011). Long-term effects ofAAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res 2014;114:101–108. 心衰基因治疗逐渐进入人们的视野，心衰心脏中插入 SERCA2a 基因或许可作为一种治疗策略，因为 SERCA2a 基因在心肌收缩中扮演着重要的角色。CUPID 研究纳入 39 名心衰患者，接受冠脉内注射 SERCA2a1 型腺相关病毒或安慰剂。最初结果表明基因转染或改善相关替代终点并减少心血管事件。纳入